

Cyprus

Population (January 2013):	865 878
Human development Index (2013):	0.845
HAV vaccine recommendations:	HAV vaccination is recommended but not funded by the National Health System, with the exception of vaccination administered for medical conditions. Vaccination is given on specific indication only
Seroprevalence studies by quality score:	score 0: 1 studies score 1: 1 study score 2: 0 studies
Seroprevalence studies timeframe:	1975–1998

Seroprevalence assessment*: **very low**

Incidence assessment: **very low**

Susceptibility in adults*: **moderate**

*assessment based on data from the early 1990s

The only article providing estimates seroprevalence among Cypriots is a study conducted in 1979 on a sample of 124 Turkish Cypriots and reports 100% prevalence by 30 years of age (Weiland 1979). After 1990, one study was retrieved providing data among children and soldiers in Cyprus. The estimated seroprevalence by age 18 are well below 10% (Cyprus_Figure 1). In the light of the available data, Cyprus in the 1990s could be considered a very low endemicity country, although with high likelihood of important geographical variation.

Cyprus_Table 1. Hepatitis A seroprevalence level by time period

	Very low endemicity	Low endemicity	Intermediate endemicity
1975–1989			
1990–1999			
2000–2013			

The reported incidence data obtained from TESSy show a very low incidence rate (≤ 0.5 cases per 100 000) in the period 2006 to the present (Cyprus_FFfigure 2).


Considering the very low seroprevalence reported during the 1990s among individuals aged 18 years or below and the very low reported incidence in Cyprus after 2006, we expect young adults to be at high susceptibility at present. Nevertheless the data from previous decades indicates very high level of seroprevalence in the older birth cohorts. Therefore the overall susceptibility among adults is to be considered moderate.

Cyprus_Figure 1 (panel a). Summary of seroprevalence in Cyprus, by age and time period

Panel a.1: 1975–1989

No data available


Panel a.2: 1990–1999



Panel a.3: 2000–2013

No data available

Cyprus_Figure 2. Reported incidence of hepatitis A, Cyprus, 2006–2013



Bibliography

1. Hadjipanayis A, Hadjichristodoulou C, Kallias M, Sava K, Petsa A, Demetriadou K, et al. Prevalence of antibodies to hepatitis A among children and adolescents in Larnaca area, Cyprus. *Eur J Epidemiol.* 1999 Nov;15(10):903-5.
2. Weiland O, Berg JV, Back E, Lundbergh P. Immunoglobulin prophylaxis against hepatitis A among Swedish UN soldiers in an endemic region. *Infection.* 1979;7(5):223-5.